The FDA has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

Amikacin Inhale (BAY 41-6551), is the development name for an integrated drug-device combination, developed by Bayer HealthCare in collaboration with Nektar Therapeutics as an adjunctive therapy for intubated and mechanically ventilated patients with Gram-negative pneumonias.

Ciprofloxacin dry powder for inhalation is the development name of a drug-device combination currently being investigated in non-cystic fibrosis bronchiectasis (NCFB) by Bayer HealthCare.